Evofem Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except par value and share data)
| As of | ||
|---|---|---|
| June 30, 2026 | December 31, 2025 | |
| Assets | ||
| Current assets: | ||
| Restricted cash and cash equivalents | $285 | $578 |
| Trade accounts receivable, net | 2,497 | 12,480 |
| Inventories | 2,155 | 1,129 |
| Prepaid and other current assets | 1,145 | 1,097 |
| Total current assets | 6,082 | 15,284 |
| Property and equipment, net | 412 | 418 |
| Operating lease right-of-use assets | 118 | 182 |
| Intangible asset, net (Note 7) | 869 | 4,348 |
| Other noncurrent assets | 41 | 42 |
| Total assets | $7,522 | $20,274 |
| Liabilities, convertible and redeemable preferred stock and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $12,150 | $13,153 |
| Notes - carried at fair value (Note 4) | 18,616 | 20,097 |
| Notes - carried at fair value - related party (Note 4) | 1,219 | 1,352 |
| Convertible notes - Adjuvant - related party (Note 4) | 34,010 | 32,770 |
| Short-term debt | 362 | 147 |
| Accrued expenses | 1,571 | 1,292 |
| Accrued compensation | 2,177 | 2,587 |
| Operating lease liabilities – current | 114 | 128 |
| Derivative liabilities | 6,913 | 1,006 |
| Contingent liabilities - current (Note 7) | 312 | 272 |
| Other current liabilities | 11,171 | 12,016 |
| Total current liabilities | 88,615 | 84,820 |
| Operating lease liabilities – noncurrent | 4 | 54 |
| Contingent liabilities - noncurrent (Note 7) | 1,393 | 4,837 |
| Total liabilities | 90,012 | 89,711 |
| Commitments and contingencies (Note 7) | - | - |
| Convertible and redeemable preferred stock, $0.0001 par value, senior to Common Stock | ||
| Series E-1, F-1 and G-1 convertible and redeemable preferred stock, 10,000, 95,000 and 5,000 shares authorized; 2,836 and 2,412 shares of E-1 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; 26,280 shares of F-1 issued and outstanding at both June 30, 2026 and December 31, 2025, and 1,592 and 1,618 shares of G-1 issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 5,026 | 4,899 |
| Stockholders’ deficit: | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of both June 30, 2026 and December 31, 2025 | - | - |
| Common Stock, $0.0001 par value; 3,000,000,000 shares authorized; 132,530,081 and 126,685,925 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 13 | 13 |
| Additional paid-in capital | 831,875 | 831,859 |
| Accumulated other comprehensive loss | (5,385) | (8,818) |
| Accumulated deficit | (914,019) | (897,390) |
| Total stockholders’ deficit | (87,516) | (74,336) |
| Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit | $7,522 | $20,274 |
See accompanying notes to the condensed consolidated financial statements (unaudited).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.